CClinicalTrials.gg
Active, not recruitingNCT05671380Updated Apr 13, 2026

A Pragmatic Trial of Chronic Disease Approaches to Ameliorate Tobacco Related Cardiovascular Disease Health Disparities

An interventional study of Longitudinal Proactive Outreach (LPO). and Ask-Advice-Connect (AAC) in Tobacco Use Cessation, Cardiovascular Diseases and Tobacco Use, sponsored by University of Minnesota. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by University of Minnesota · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This project will evaluate a proactive outreach intervention for tobacco cessation among primary care BIPOC populations who smoke in two health systems across the region. Compared with Whites, BIPOC populations in the US experience disproportionate health consequences from commercial cigarette use. Few evidence-based cessation treatments (EBCTs) have been specifically developed, evaluated, or implemented for BIPOC populations. Moreover, uptake of EBCT (e.g. medication, counseling) is lower among BIPOC populations. Reasons for the failure to engage BIPOC patients in EBCTs are complex and multi-level (e.g., patient, provider, healthcare system). To address these gaps, the investigators will assess the added effectiveness of an approach to augment the standard of care with longitudinal proactive outreach to connect BIPOC adults with EBCT. The proposed multi-level intervention leverages the electronic health record to identify patients who smoke, who can then be proactively engaged via culturally tailored outreach to connect them to EBCT. The proactive approach may circumvent experiences of bias within the healthcare system and thus enhance engagement.

02

Conditions studied

  • Tobacco Use Cessation
  • Cardiovascular Diseases
  • Tobacco Use
  • Smoking
  • Smoking Cessation
03

In context

Tobacco Use Cessation

62 studies on the registry are indexed under Tobacco Use Cessation; 31 are open to participants now.

This study's enrollment of 700 is above the median of 223 across 61 interventional studies indexed under Tobacco Use Cessation.

Browse Tobacco Use Cessation studies →

Lead sponsor

University of Minnesota is the lead sponsor of 1,184 studies on the registry; 195 are open to participants now.

Of its 132 completed or terminated interventional studies of FDA-regulated products, 91 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • English or Spanish-speaking BIPOC patients within the Hennepin Healthcare or MCHS system. BIPOC patients are any patients with a chart identified race that is not White, and will be verified by self-report from the baseline survey.
  • Currently smoke >1 cigarette over the past 30 days
  • Must have address or telephone number in the electronic health record

Exclusion criteria

Exclusion Criteria:

  • Electronic health record documented cognitive impairment or legal guardianship
  • Patients who have opted out of reserach studies
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
700 participants (actual)

Study arms

  • Active comparator
    Enhanced Usual Care: Ask-Advice-Connect (AAC)

    AAC participants will receive care through their primary care provider as usual (with the caveat that providers in the clinics will be trained to provide AAC). AAC includes enhanced access to State Quitline and Nicotine Replacement Therapy.

    Behavioral: Ask-Advice-Connect (AAC)

  • Experimental
    AAC + Longitudinal Proactive Outreach (LPO)

    AAC+LPO participants will receive AAC plus an MI tailored outreach call at baseline and at 3, 6, and 9 months post-enrollment. AAC includes enhanced access to State Quitline and Nicotine Replacement Therapy.

    Behavioral: Longitudinal Proactive Outreach (LPO). · Behavioral: Ask-Advice-Connect (AAC)

Interventions

  • BehavioralLongitudinal Proactive Outreach (LPO).

    All participants will receive personalized invitation materials (in their preferred language) with messages culturally and linguistically tailored to BIPOC communities, guided by the literature on culturally adapting evidence-based interventions. The study team will tailor these resources in collaboration with the CE core. The tailored mailed packet will include an invitation letter and a brochure describing the types of tobacco treatment services available from their health system and from Quit Partner. One week after the written materials are sent, participants assigned to this condition will receive LPO by a MI-trained coach. The MI outreach call protocol will consist of 6 contact attempts over two weeks.The MI outreach call protocol will be repeated at 3, 6, and 9 months for a total of four outreach cycles because participants may not have quit or may have relapsed.

  • BehavioralAsk-Advice-Connect (AAC)

    Licensed Practical Nurses will be trained to ask all patients if they smoke, document smoking status in the EHR, advise patients to stop smoking, and complete an electronic referral to Quit Partner or the smoking cessation clinic. AAC will be designed to connect participants to Quit Partner Minnesota to receive tobacco cessation counseling. Quit Partner™ is a family of programs available to help Minnesota residents quit commercial tobacco, administered by the Minnesota Department of Health (MDH). Quit Partner programs are provided by National Jewish Health (NJH). Any Minnesota resident can access a free 2-week supply of Nicotine Replacement Therapy (NRT). Uninsured and underinsured residents can access the full Quit Partner programs, including free one-on- one coaching, more NRT, and additional supports. Quit Partner also offers four population- specific programs and calls are available in several languages.

06

What researchers measure

Primary outcomes

  1. 7-day point-prevalence smoking abstinence at 18 months

    7-day point prevalence abstinence from combustible tobacco will be verified at 18 months post-enrollment. Surveys to self-report abstinence will be provided at 6, 12, and 18 months. Self-reported smoking abstinence will be verified using expired carbon monoxide as the primary method with salivary cotinine as an alternative method at the 18-month follow-up. Participants with a CO of \< 6 ppm will be considered abstinent. Participants with a salivary cotinine \< 10 ng/ml will be considered abstinent.

    Time frame: 18 months

Secondary outcomes

  1. Change in Theory of Planned Behavior Questionnaire (TPB-Q) Score

    The TPB-Q is a commonly used and thoroughly validated instrument that maps onto the three predictors of health behavior change in the Theory of Planned Behavior: attitudes about the behavior, perceived subjective norms about the behavior, and perceived control over the behavior. The TPB-Q items have common wording tapping into those three domains, but the scale was developed such that the items are customized to the specific behavioral goal of an intervention, and thus still comparable across behaviors.

    Time frame: 0, 6, 12, and 18 months

  2. Change in Treatment utilization.

    Self-reported utilization of evidence-based cessation treatment (EBCT) will be assessed during the 18-month follow-up from any source. The main treatment outcome will be initiation of counseling with Quit Partner or the participant's healthcare provider, combined with medication treatment utilization. Initiation of counseling treatment with the Quit Partner will be defined as completion of a warm transfer or electronic referral to the quitline. Initiation of medication treatment will be defined as using one or more tobacco dependence medications (e.g., NRT, bupropion or varenicline) in the 18-month follow-up period. Additional treatment utilization outcomes include individual use of counseling or medication and use of any form of EBCT.

    Time frame: 6, 12, and 18 months

  3. Change in Overall Quality of Life

    Overall quality of life will be assessed using a single-item numerical linear analogue self-assessment from 0 (as bad as it can be) to 10 (as good as it can be) via survey through 18 months post-enrollment.

    Time frame: 0, 6, 12, and 18 months

07

Study locations

3 sites
  • Hennepin Healthcare
    Minneapolis, Minnesota 55415, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic Health System
    Rochester, Minnesota 55902, United States
08

References and documents

Publications

  • Fu SS, Hammett P, Nelson D, Busch A, McKinney W, Sharma P, Patten CA, Gutierrez Sacasa N, Andreae L, Japuntich S. Evaluating chronic disease approaches to ameliorate tobacco-related health disparities: Study protocol of a hybrid type 1 implementation-effectiveness trial. Contemp Clin Trials Commun. 2024 Oct 16;42:101380. doi: 10.1016/j.conctc.2024.101380. eCollection 2024 Dec. PubMed 39498443 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05671380
Lead sponsor
University of Minnesota
Responsible party
Sponsor
First posted
Jan 4, 2023
Start date
May 5, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

Steven Fu, MD, MSCE
principal investigator · Minneapolis Veterans Affairs Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion